Redimune® NF Liquid, a ready-to-use, high-concentration intravenous immunoglobulin therapy preparation, is safe and typically well tolerated in the routine clinical management of a broad range of conditions

Clinical and Experimental Immunology

Volumn 152, Issue 1, 2008, Pages 45-49

  Piguet, D ^a   Tosi, C ^b   Luthi J M ^c   Andresen, I ^d   Juge, O ^e  

^a Haematology Oncology   (Switzerland)

^b REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^c Onkologie Zentrum   (Switzerland)

^d CSL Behring AG   (Switzerland)

^e Neurology Clinic   (Switzerland)

Author keywords

Immunoglobulin; IVIG; Liquid; Observational study; Safety

Indexed keywords

IMMUNOGLOBULIN; REDIMUNE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHILL; CLINICAL PRACTICE; CONTROLLED STUDY; DIZZINESS; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GRAFT VERSUS HOST REACTION; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOTHERAPY; INFUSION RATE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEOPLASM; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; PHYSICIAN; PRIORITY JOURNAL; ADOLESCENT; CHEMISTRY; CHILD; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; EVALUATION; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHEMISTRY, PHARMACEUTICAL; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEADACHE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MALE; MIDDLE AGED; NEOPLASMS; NERVOUS SYSTEM DISEASES;

EID: 40449117694     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2008.03597.x     Document Type: Article

References (13)